Qiagen N.V. (NYSE:QGEN) Receives $49.40 Average Target Price from Analysts

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been given an average recommendation of "Hold" by the ten research firms that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $49.40.

A number of brokerages have commented on QGEN. Robert W. Baird raised their price objective on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Bank of America lifted their target price on Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Finally, Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC boosted its position in Qiagen by 52.3% in the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company's stock worth $9,845,000 after purchasing an additional 84,332 shares during the last quarter. Strs Ohio purchased a new position in Qiagen in the first quarter worth $1,891,000. United Services Automobile Association purchased a new position in Qiagen in the first quarter worth $239,000. Parkman Healthcare Partners LLC boosted its position in Qiagen by 29.7% in the first quarter. Parkman Healthcare Partners LLC now owns 359,644 shares of the company's stock worth $14,440,000 after purchasing an additional 82,372 shares during the last quarter. Finally, Petrus Trust Company LTA boosted its position in Qiagen by 83.9% in the first quarter. Petrus Trust Company LTA now owns 10,577 shares of the company's stock worth $425,000 after purchasing an additional 4,827 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Stock Down 0.6%

Qiagen stock traded down $0.30 during mid-day trading on Thursday, reaching $48.34. The stock had a trading volume of 770,537 shares, compared to its average volume of 1,199,075. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The stock's 50-day simple moving average is $44.83 and its 200-day simple moving average is $42.66. The firm has a market capitalization of $10.75 billion, a PE ratio of 121.20, a price-to-earnings-growth ratio of 2.46 and a beta of 0.68.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The firm had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same quarter last year, the firm posted $0.44 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd will be given a $0.25 dividend. The ex-dividend date of this dividend is Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's dividend payout ratio is currently 62.50%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.